Perrigo (PRGO) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Perrigo (PRGO) over the past year, gaining 28.0% versus a loss of 30.1%. Over five years, XERS leads with a +424.0% price change compared with -67.6% for PRGO. Perrigo is the larger company by market cap ($2.08 billion vs $1.91 billion), about 1.1 times the size, while Xeris Biopharma is growing revenue faster (+43.7% vs -2.8%).
On valuation, Perrigo trades at a lower forward P/E (6.3x vs 28.3x for Xeris Biopharma). Perrigo pays a dividend yielding 7.70%, while Xeris Biopharma does not currently pay one. Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -33.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRGO | XERS |
|---|---|---|
| Share price | $15.06 | $10.48 |
| Market cap | $2.08B | $1.91B |
| 1-day change | +3.86% | +2.85% |
| YTD return | +8.19% | +33.50% |
| 1-year return | -30.12% | +27.96% |
| 5-year return | -67.58% | +424.00% |
| Forward P/E | 6.28 | 28.32 |
| EPS (TTM) | $-12.28 | $-0.10 |
| Dividend yield | 7.70% | 0.00% |
| Annual dividend | $1.16 | $0.00 |
| Revenue (latest FY) | $4.25B | $291.85M |
| Revenue growth (YoY) | -2.75% | +43.72% |
| Net income (latest FY) | $-1.43B | $554.00K |
| Gross margin | 35.14% | 85.41% |
| Operating margin | -26.39% | 8.53% |
| Net margin | -33.51% | 0.19% |
| 52-week high | $22.02 | $11.33 |
| 52-week low | $9.23 | $5.25 |
| Distance from 52-week high | -31.61% | -7.50% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +9.56% | +22.71% |
| Average volume | 2.80M | 2.17M |
| Shares outstanding | 138.37M | 182.32M |
| Employees | 8,100 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed PRGO by 58.1 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.70% vs 0.00%).
- Xeris Biopharma is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -33.5 cents for Perrigo.
- Xeris Biopharma grew revenue faster in its latest fiscal year (+43.72% vs -2.75%).
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
PRGO vs XERS FAQ
Which is bigger, Perrigo or Xeris Biopharma?
Perrigo (PRGO) is larger, with a market capitalization of $2.08B compared with $1.91B for Xeris Biopharma (XERS).
Which stock has performed better over the past year, PRGO or XERS?
XERS returned +27.96% over the past 12 months, compared with -30.12% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Perrigo or Xeris Biopharma?
Perrigo pays a dividend yielding 7.70%, while Xeris Biopharma does not currently pay a regular dividend.
Are Perrigo and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.